First Time Loading...

Sonoma Pharmaceuticals Inc
NASDAQ:SNOA

Watchlist Manager
Sonoma Pharmaceuticals Inc Logo
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Watchlist
Price: 0.156 USD 1.89% Market Closed
Updated: May 4, 2024

Operating Margin
Sonoma Pharmaceuticals Inc

-33.7%
Current
-36%
Average
7.5%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-33.7%
=
Operating Profit
-4.1m
/
Revenue
12.3m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
2.4m USD
-34%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-83%
US
Eli Lilly and Co
NYSE:LLY
698.5B USD
32%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
DK
Novo Nordisk A/S
CSE:NOVO B
3.8T DKK
45%
US
Johnson & Johnson
NYSE:JNJ
359.3B USD
28%
US
Merck & Co Inc
NYSE:MRK
322.8B USD
11%
UK
AstraZeneca PLC
LSE:AZN
186.8B GBP
19%
CH
Novartis AG
SIX:NOVN
179.8B CHF
27%
CH
Roche Holding AG
SIX:ROG
173.2B CHF
32%
US
Pfizer Inc
NYSE:PFE
157B USD
19%
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Country US
Market Cap 2.4m USD
Operating Margin
-34%
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Eli Lilly and Co
NYSE:LLY
Country US
Market Cap 698.5B USD
Operating Margin
32%
Dechra Pharmaceuticals PLC
LSE:DPH
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Novo Nordisk A/S
CSE:NOVO B
Country DK
Market Cap 3.8T DKK
Operating Margin
45%
Johnson & Johnson
NYSE:JNJ
Country US
Market Cap 359.3B USD
Operating Margin
28%
Merck & Co Inc
NYSE:MRK
Country US
Market Cap 322.8B USD
Operating Margin
11%
AstraZeneca PLC
LSE:AZN
Country UK
Market Cap 186.8B GBP
Operating Margin
19%
Novartis AG
SIX:NOVN
Country CH
Market Cap 179.8B CHF
Operating Margin
27%
Roche Holding AG
SIX:ROG
Country CH
Market Cap 173.2B CHF
Operating Margin
32%
Pfizer Inc
NYSE:PFE
Country US
Market Cap 157B USD
Operating Margin
19%

Profitability Report

View the profitability report to see the full profitability analysis for Sonoma Pharmaceuticals Inc.

Full Profitability Report

See Also

Summary
SNOA intrinsic value, competitors valuation, and company profile.
DCF Valuation
SNOA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SNOA stock valuation using valuation multiples.
Wall Street Estimates
SNOA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SNOA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-33.7%
=
Operating Profit
-4.1m
/
Revenue
12.3m
What is the Operating Margin of Sonoma Pharmaceuticals Inc?

Based on Sonoma Pharmaceuticals Inc's most recent financial statements, the company has Operating Margin of -33.7%.

ALPHA SPREAD
Join more than 134,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.